After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
SOURCE Insmed Incorporated
A month after Fed Chair Janet Yellen's comments, ETFs covering both groups are pushing towards new highs on strong fundamental backdrops.
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Insmed (INSM) plunged Monday after the company announced it would conduct two Phase III studies of its lead drug candidate Arikayce, which indicates a delay in its FDA approval.
Insmed (INSM) soared Wednesday after the FDA granted Breakthrough Therapy Designation for Arikayce, the biotech company's only drug candidate.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.